RxDoctor Payments Data

Krishna Shanmugam, MD

Ophthalmology · Lubbock, TXNPI 1518286558

Payments from drug & device makers

$3,365in general payments, 2019–2025

Across 91 payments — averaging $36.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$819
  • NEW World Medical,inc.$349
  • Bausch & Lomb Americas Inc.$338
  • AbbVie$324
  • Iridex Corporation$305
  • Alcon$211
  • plus $1K from 16 others

What the payments were for

  • Speaking & faculty fees$1916%
  • Food & beverage$3,17494%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,365 in reported general payments places this provider in the 60th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$218,742
Medicare patients
327
Services billed
1,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lotemax SmLoteprednol Etabonate199$48,897
ProlensaBromfenac Sodium136$46,065
VyzultaLatanoprostene Bunod97$31,910
LumiganBimatoprost28$15,131
CombiganBrimonidine Tartrate/Timolol40$13,886
Prednisolone Acetate209$11,362
RocklatanNetarsudil Mesylat/Latanoprost17$8,923
MoxifloxacinMoxifloxacin Hcl355$6,932
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol22$4,341
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat235$3,513
Difluprednate33$3,146
Latanoprost392$2,918
Travoprost14$2,080
Timolol Maleate83$900
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha40$796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa$13$94,962335 claims
Bausch & Lomb Americas Inc.Vyzulta$338$31,91097 claims
AbbVieLumigan, Combigan$324$29,01768 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →